Life Science

A selective, orally bioavailable inhibitor of Akt1, 2, and 3 (Kis = 0.08, 2, and 2.6 nM, respectively) inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies.

A selective, orally bioavailable inhibitor of Akt1, 2, and 3 (Kis = 0.08, 2, and 2.6 nM, respectively) inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies.

A selective, orally bioavailable inhibitor of Akt1, 2, and 3 (Kis = 0.08, 2, and 2.6 nM, respectively) inhibits the proliferation of human cancer cell lines with Akt pathway activation and various cell lines derived from hematologic malignancies.

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A potent CCKB/gastrin receptor antagonist that exhibits selective binding for CCKB compared to CCKA exhibits synergistic inhibitory effects on the cell viability of human gastric cancer cells when administered in combination with the selective

A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC₅₀ values of 0.4 and 7 &muM, respectively inhibits proliferation of human breast cancer MCF-7 cells (10 nM)

A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC₅₀ values of 0.4 and 7 &muM, respectively inhibits proliferation of human breast cancer MCF-7 cells (10 nM)

A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC₅₀ values of 0.4 and 7 &muM, respectively inhibits proliferation of human breast cancer MCF-7 cells (10 nM)

An IDH1 inhibitor.

An IDH1 inhibitor.